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INTRODUCTION
Glioblastoma is most aggressive type of primary brain tumor, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. Regardless of advances in microsurgery techniques, radiotherapy and chemotherapy, the survival rate for glioblastoma remains very low. 1) Developing a new treatment strategy is a challenge requiring urgent attention.
Glioblastoma is believed to develop as a result of accumulations of genetic lesions. 2) Recently, growing attention has been focused on the oncogene Akt, also known as protein kinase B (PKB). [3] [4] [5] Three isoforms of Akt (Akt 1, 2, and 3) have been identified that are closely related to each other, sharing up to 80% of amino acid homology. 6, 7) Akt is a serine/threonine kinase activated by various growth factors, such as phosphoinositide 3-kinase, epidermal growth factor and platelet-derived growth factor. 7) There are sequential steps in Akt activation, including constitutive phosphorylation of Thr450, translocation to the membrane induced by growth factors and phosphorylation of Thr308 and Ser473 at cell membrane. Phosphorylation of Thr308 is necessary for the Akt activation, which reaches a maximum level by phosphorylation of Ser473. 8) Akt plays a central role in tumorigenesis through promotion of cell survival by inhibiting apoptosis and mediating cell proliferation and alters angiogenic potential. In view of the fact that up to 80% of all glioblastoma expresses elevated levels of Akt, therefore, activation of the Akt pathway could have a potential not only in development of human glioblastoma but in aggressiveness.
To date, higher Akt expression and activation has been shown to be correlated with poor prognosis in a number of tumor types, including gastric carcinomas, hepatocellular carcinoma, leukemia, breast cancer, and pancreatic cancer. [11] [12] [13] [14] [15] In the current study, the expression of phosphorylated-Akt (pAkt) was immunohistochemically examined in 64 patients with glioblastoma, and its relationship with clinicopathologic factors and its prognostic significance were retrospectively evaluated.
MATERIALS AND METHODS

Patients and specimens
Tissue specimens were obtained from the 64 patients with pathologically confirmed glioblastoma treated with radiation therapy after surgery (or biopsy) at the Gunma University Hospital (Maebashi Japan), Takasaki National Hospital (Takasaki Japan), and Maebashi Red Cross Hospital (Maebashi Japan) between 1987 and 2005 (Patients, who were lost to follow up within six months and those for whom paraffin-embedded tumor samples were not available, were excluded). Table 1 shows the clinical characteristics of the 64 patients. The mean ± standard deviation (SD) and median follow-up period was 16.2 ± 12.4 and 12 months, respectively (range: from 1 to 62 months). All patients were followed up with a minimum 3 years or until they died. Sixty patients died due to tumor progression and 4 patients were alive more than 3 years. The mean ± SD and median of age were 56.2 ± 16.3 and 59 years old, respectively (range: from 9 to 80 years old). Twenty-nine patients were aged ≤60 years and 35 were aged >60 years. The numbers of male and female patients were 41 and 23, respectively. Gross or sub-total removal was performed in 20 patients, partial removal or biopsy in 41 patients and unknown in 3 patients. The mean ± SD and median radiation dose were 57.5 ± 8.2 Gy and 60 Gy, respectively. Regarding the radiation therapy protocol, conventional radiation therapy (10 Gy/5 fraction/5 days/ week) was performed in most of patients. In some patients, hyper-or hypo-fractionated regimens (e.g. 1 Gy/fraction; 2 fractions/day; 5 days/ week or 2.5 Gy/fraction; 2 fractions/ day; 2 days/week) were used. Therefore, the biological effective dose (BED: α/β ratio = 10.0) was used for analysis. (e.g. 60 Gy/30 fractions = BED of 72 Gy). The mean ± SD and median BED were 69.3 ± 9.5 Gy and 72 Gy, respectively. Forty-three patients were irradiated with BED 72 ≤ Gy and 21 patients were irradiated with BED >72 Gy. Chemotherapy was performed in 43 patients as initial treatment before and/ or after irradiation. The histological diagnosis was performed based on the WHO Classification of Tumors of the Nervous System (2000).
2)
Immunohistochemistry
The tissue specimens were cut into 4 μm sections on cylan-coated slides, then were deparaffinized and hydrated.
For antigen retrieval, they were heated by microwave for 90 minutes in Dako Target Retrieval Solution (Dako, CA, U.S.A.) at 95.0°C and were cooled for 20 minutes. After washing with Tris Buffered Saline (TBS), nonspecific binding was blocked with peroxidase-blocking solution (Dako) for 15 minutes. The specimens were incubated overnight at 4.0°C with Anti-Phospho-Akt (Ser473) antibody (Cell Signaling Technology, Beverly, MA) 16) diluted with antibody diluent (Dako) at 1:200. Then, they were washed with TBS. They were incubated with a labeled-polymer conjugated second antibody EnVision + kit (Dako) for 45 minutes. After washing in TBS, the specimens were developed with 3,3'-diaminobenzidine tetrahydrochloride (Dako) for 7 minutes. Specimens were slightly counterstained with hematoxylin, and finally dehydrated and mounted. As a positive control, a known positive control (cervical cancer) specimen was handled in parallel. As a negative control, a specimen was treated without a primary antibody in the incubation step. 
Evaluation
All immunohistochemically stained slides were pathologically assessed by one of the authors (K.O), without knowledge of the clinical data. The cell nuclei and cytoplasm of more than 500 tumor cells were evaluated in each specimen. The percentage of staind tumor cells was estimated among the total number of the tumor cells and the cases were scored as 0%, 0-10%, 10-50% or >50%. Positive staining was defined when more than 50% of either nuclear or cytoplasma of the tumor cells were stained in each specimen. The correlation between pAkt expression and overall survival were evaluated. The cut-off value was established as a positive finding.
Statistical analysis
The overall survival period was calculated from the date of operation to the date of death or last follow-up. The Kaplan-Meier method was used for the overall survival curves, and differences were statistically analyzed with the log-rank test. The multivariate analysis for overall survival was applied with the Cox proportional hazard model with a 95.0% confidence interval. The correlation matrix was calculated by using Pearson's product moment correlation coefficient. The differences were considered statistically significant at p value < 0.05.
RESULTS
Glioblastomas showed either or both cytoplasmic and nuclear positive findings for pAkt (Fig. 1) . The number of cases scored as 0%, 0-10%, 10-50% and >50% were 20, 13 12 and 19, respectively. The number of cytoplasmic and nuclear positive specimens were 17 (28.3%) and 3 (4.7%), respectively (one specimens showed both cytoplasmic and nuclear positive). A total of 29.7% (19/64) of tissue specimens had greater than 50% pAkt positivity.
For all patients, the median survival periods was 12 months and 2-year overall survival rate was 17.2%. The median survival periods of the patients with pAkt positive and negative tumor were 10 and 14 months, respectively. Two years overall survival rate of the pAkt positive and negative patients were 0% and 24.4%, respectively. Survival rate of the patients with pAkt positive tumor was significantly lower than that of the patients with pAkt negative tumors (p = 0.004; Fig. 2) .
The overall survival based on clinical characteristics is shown in Table 1 . The 2-year survival rate of patients on whom had been performed either gross total removal or subtotal removal was 35.0%, significantly higher than 7.3% of patients whom had been performed either partial resection or biopsy, (p = 0.047). Whereas, the 2-year survival rates of patients aged ≤60 and >60 years were 17.1% and 17.2%, respectively (p = 0.31). The 2-year survival rates for male and female were 12.2% and 26.1%, respectively (p = 0.48). The 2-year survival rates of patients irradiated with BED ≤72 Gy and BED >72 Gy were 16.3% and 19.0%, respectively (p = 0.59). The 2-year survival rates of patients without and with chemotherapy were 11.8% and 20.9%, respectively (p = 0.44). Table 2 shows the multivariate analysis for 2-year survival. The extent of surgery had the strongest and statistically significant impact on 2-year survival (standard regression coefficient = 0.336, p = 0.01). The pAkt expression had the second strongest impact (standard regression coefficient = -0.23, p = 0.06).
Because extent of surgery and expression of pAkt were significant factors for survival, we performed additional analysis regarding an interaction between extent of surgery and expression of pAkt. There was no significant correlation between extent of surgery and pAkt expression (p = 0.33). Among patients on whom had been performed either gross total removal or subtotal removal, patients with pAkt positive tumor had a significantly worse survival than those with pAkt negative tumor (2-year overall survival rate: 0% vs 43.8%, p = 0.04). Among patients on whom had been performed either partial resection or biopsy, 2-year overall survival rate of pAkt positive and negative patients were 0% and 10.7%, respectively (p = 0.17).
DISCUSSION
The role of Akt in tumorigenesis has been studied extensively in recent years. Elevated Akt activity has been observed in numerous types of human cancers. 17) In this study, to better understand the role of Akt in glioblastoma progression, immunohistochemistry was used to investigate Akt activity in 64 cases of glioblastoma lesions using an antibody specific for phosphorylated Akt at Ser-473. Our results demonstrated that higher pAkt expression is inversely correlated with patient survival in glioblastoma. According to sub-group analysis, pAkt expression can be a promising biomarker for survival especially among patients performed radical surgery though the number of patients was small. Regarding clinical factors, extent of surgery was significant factor by univariate analysis and multivariate analysis, as most previous demonstrated. Multivariate analysis showed that pAkt expression was secondly strongest independent factor, following extent of surgery.
Yet, Akt pathway activation is complex and remains imperfectly defined for two main rationales. Firstly, the number of identified physiological Akt substrates is expanding rapidly. 18) Secondly, there are additional higher-order structural requirements for Akt recognition and phosphorylation of substrates in vivo. Subcellular location of Akt also adds more complexity to the situation. In resting nonstimulated cells, the majority of Akt exists in the cytoplasm. Activation of Akt occurs at the plasma membrane and has been shown in several studies to be followed by its translocation to both the cytosol and nucleus. [19] [20] [21] However, many of the substrates of PKB/Akt are proteins that function in the nucleus and subject to simultaneous regulation by other signaling pathways. 22) Furthermore, difference of significance between nuclear and cytoplasmic expression of pAkt is still unclear.
Therefore to date, PKB/Akt seems to be activated in cells exposed to diverse stimuli such as hormones, growth factors, and extracellular matrix components. The activation mechanism occurs downstream of phosphoinositide 3-kinase (PI3K). PI3K generates phosphatidylinositol-3,4,5-trisphosphate (PIP3), a lipid second messenger essential for the translocation of PKB/Akt to the plasma membrane where it is phosphorylated and activated by phosphoinositidedependent kinase-1 (PDK-1).
23)
The main physiological lipid substrate for PTEN, which is a dualfunction lipid and protein phosphatase, is PIP3, the product of PI3K. PTEN dephosphorylates PIP3 and thus acts as a negative regulator of PI3K signaling. 23) Absence of PTEN correlates with activation of PKB/Akt in tumor cell lines. 24) PTEN was shown to be frequently mutated in the advanced stages of a number of human cancers, particularly glioblastoma. Related to PTEN, expression of PI3K and pAkt has been correlated with progression of glioblastoma both in vitro and animal model. [25] [26] [27] Mizoguchi et al. demonstrated the immunohistochemical study of pAkt in malignant glioma patients. 28) They showed that pAkt was significantly correlated with the progression of anaplastic astrocytoma to GMB, and was marginally predictive of worse prognosis in malignant glioma. To our knowledge, this is the first study to analyze the phosphorylation of Akt in glioblastoma, and its association with patient survival.
Glioblastoma treatment remains a challenge. Although multimodality therapy (operation, radiotherapy and chemotherapy) is performed, the median survival time of the patients with glioblastoma is still 12 months over the last few decades. Recently, Stupp et al. demonstrated that concurrent radiotherapy and temozolomide followed by adjuvant temozolomide was a standard therapy for newly diagnosed glioblastoma. 29) Furthermore, molecular biological investigation on this trial observed that MGMT methylation was a crucial predictive factor in the patients treated with this regimen. 30) Our study didn't involve patients treated with concurrent temozolomide and radiotherapy since the drug was not available for medical use in Japan until 2006. Hence, further study including patients treated with temozolomide should be explored.
Despite the intensive treatment, most of glioblastoma patients have local disease progression. However, Nakagawa et al. reported that very high dose radiotherapy (90 Gy/ 45 fractions) using the rotational MLC conformal therapy technique could achieve local tumor control in 7 of 13 glioblastoma patients whereas local tumor control was achieved only in 2 of 19 patients by lower dose irradiation (e.g. 80 Gy/ 40 fractions). According to this report, the pattern of failure of these locally control patients was mostly seeding of tumor to the out of irradiated area. 31) Current preclinical studies suggest that it may be due to a migration ability of glioblastoma. 32) Specific antimigratory compounds are anticipated to be of use to conventional radio-and/or chemotherapy. 33) Also, targeting therapy of Rapamycin/ mTOR, which is a downstream of the PI3K/Akt signaling pathway, could provide the antitumor effect by inducing apoptosis and inhibiting migration. 34) To understand of biological molecular profile of glioblastoma provides a optimizing targeting therapy.
To sum up, our result shows some evidence that higher pAkt expression predicts a poor prognosis in glioblastoma patients and inhibition of pAkt represents a future area of research.
